- Home
- BNTC vs CLLS Comparison
BNTC vs CLLS Comparison
Compare BNTC & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNTC | CLLS |
|---|---|---|
| Founded | 1995 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 454.2M | 394.4M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BNTC | CLLS |
|---|---|---|
| Price | $13.68 | $3.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $27.67 | $8.33 |
| AVG Volume (30 Days) | ★ 162.0K | 16.7K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.85 | $2.35 |
| 52 Week High | $16.76 | $5.48 |
Technical Indicators
Market Signals| Indicator | BNTC | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 60.62 | 68.24 |
| Support Level | $11.28 | $3.41 |
| Resistance Level | $13.79 | $4.24 |
| Average True Range (ATR) | 0.83 | 0.18 |
| MACD | 0.07 | 0.08 |
| Stochastic Oscillator | 89.02 | 99.12 |
Price Performance
Historical ComparisonAbout BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.